Seeking Alpha

Cadence Pharmaceuticals (CADX -15.8%) takes a hit after announcing plans for a $75M secondary...

Cadence Pharmaceuticals (CADX -15.8%) takes a hit after announcing plans for a $75M secondary stock offering. The company plans to use the majority of the funds for research and development of its injectable acetaminophen drug Ofirmev.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|